Vanguard Intl Div Apprec Idx ETF
Latest Vanguard Intl Div Apprec Idx ETF News and Updates
What to Expect for Novartis’s Subsidiary Alcon in 2018
In 1Q17, 2Q17, and 3Q17, Novartis’s (NVS) subsidiary Alcon generated revenues of $1.4 billion, $1.5 billion, and $1.5 billion, respectively.
Novartis’s Crizanlizumab Demonstrates Positive Results in Trials
In December 2017, Novartis presented the results from the post-hoc subgroup analysis of the phase 2 Sustain trial.
Perjeta Could Significantly Boost Roche’s Revenue Growth in 2018
In December 2017, the Food and Drug Administration approved Roche’s (RHHBY) Perjeta based on the results of its phase three Aphinity trial.
How Did DVN’s Dividend Cut Affect Its Dividend Yield?
Devon Energy Corporation’s 56.0% dividend cut in 2016 was followed by a 43.0% cut in 2017.
Esbriet Could Boost Roche’s Revenue Growth in 2H17
In the first half of 2017, Roche’s (RHHBY) Esbriet reported revenues of CHF 418.0 million, which reflected a ~16.0% growth on a YoY basis.
Welltower’s Dividend Yield Falls despite Higher Dividend
Revenue and earnings In this part, we’ll look at Welltower (HCN), a US healthcare REIT. Welltower’s revenue growth slowed from 15% in 2015 to 11% in 2016. The growth was driven by all of its segments, through rental income, resident fees and services, interest income, and other income. Its operating costs and other expenses (including interest expenses) […]